European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026: Conference Highlights

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3750
Buy Report

Published: May 01, 2026 Report Code: GDHCHT707-ST

Select Item

Explore key highlights from ESCMID Global 2026 with GlobalData’s conference analysis report. Analyze emerging therapies, infectious disease treatment trends, RSV, influenza, COVID-19, HSV, HBV, fungal infection innovations, and late-stage clinical developments presented at ESCMID 2026. Gain insight into clinical data, competitive landscape shifts, sponsor strategies, and commercial implications shaping the infectious diseases market.

Why Does ESCMID Global 2026 Matter for Your Business?

ESCMID Global remains one of the most influential infectious diseases conferences for tracking emerging therapies, clinical data, and competitive developments across viral and fungal disease markets.

This report provides a focused analysis of the key presentations, scientific sessions, and industry-sponsored symposia featured at ESCMID Global 2026, held in Munich, Germany between April 17 and 21.

You can use this report to:

  • Understand emerging trends in infectious disease therapeutics
  • Analyze late-stage clinical data and competitive developments
  • Track pipeline progress across RSV, influenza, COVID-19, HSV, HBV, and fungal infections
  • Benchmark sponsor activity and strategic positioning
  • Evaluate commercial and clinical implications of key presentations
  • Identify emerging opportunities across antiviral and antifungal markets
  • Support competitive intelligence, business development, and portfolio strategy decisions

Built on GlobalData’s proprietary pharmaceutical intelligence and conference analysis expertise, this report helps support strategic planning and market assessment across infectious disease therapeutics.

Key Insights from ESCMID Global 2026

The report highlights how innovation in antiviral and antifungal therapies continues to reshape the infectious diseases landscape.

Key themes covered include:

  • Emerging prophylactic and therapeutic strategies for viral and fungal infections
  • Increased focus on novel RSV, influenza, and COVID-19 therapies
  • Ongoing development activity across HSV and HBV treatment pipelines
  • Growing attention toward fungal infection therapeutics and resistant pathogens
  • Competitive positioning and sponsor activity across infectious disease markets
  • Clinical and commercial implications of late-breaking conference data
  • Insights into pipeline differentiation and future treatment opportunities

In addition, the report analyzes how leading pharmaceutical and biotechnology companies are positioning therapies within evolving infectious disease markets.

Scope

What Will You Learn from This ESCMID Global 2026 Highlights Report?

This report provides insight into:

  • Key clinical presentations and scientific sessions from ESCMID Global 2026

  • Emerging infectious disease therapy trends

  • Pipeline developments across major viral and fungal disease areas

  • Competitive assessment of leading therapies and sponsors

  • Clinical implications of notable conference presentations

  • Commercial outlooks and future market opportunities

  • Strategic shifts within infectious disease R&D

The report covers discussions related to:

Respiratory Syncytial Virus (RSV)

  • Zelicapavir – Enanta Pharmaceuticals

  • Nirsevimab – AstraZeneca

Influenza

  • mRNA-1010 – Moderna

COVID-19

  • Secutrelvir – Shionogi & Co

Herpes Simplex Virus (HSV)

  • Pritelivir – AiCuris

  • Adibelivir (IM-250) – Innovative Molecules

Chikungunya Virus (CHIKV)

  • EVT894 – Evotec

Hepatitis B (HBV)

  • TherVacB – Helmholtz-Zentrum fur Umweltforschung

Fungal Infections

  • Olorofim – F2G

  • SCY-247 – Scynexis

Target Buyers for This Report

This report may be valuable for:

  • Pharmaceutical companies

  • Biotechnology firms

  • Infectious disease therapeutic developers

  • Clinical development and R&D teams

  • Competitive intelligence professionals

  • Licensing and business development teams

  • Healthcare investors and analysts

  • Market access and commercialization specialists

  • Medical affairs and strategy teams

  • Consulting firms advising healthcare clients

In addition, organizations tracking infectious disease innovation and emerging treatment opportunities may use this report to support pipeline and strategic planning decisions.

How Companies Use This ESCMID Conference Analysis Report

Pharmaceutical companies, investors, and healthcare strategists can use this report to benchmark conference developments, evaluate pipeline activity, and monitor emerging therapeutic trends.

For example:

  • Pharmaceutical companies may use the report to assess competitor positioning and clinical differentiation strategies

  • Biotechnology firms can evaluate partnership and licensing opportunities linked to emerging therapies

  • Investors may analyze commercial potential and market implications of late-stage pipeline assets

  • Medical affairs teams can benchmark evolving treatment discussions and clinical priorities

  • Competitive intelligence teams may use the report to track sponsor visibility and R&D direction

  • Consulting firms can support infectious disease strategy and commercialization projects using the conference insights

Reasons to Buy

Benchmark Infectious Disease Innovation Against Industry Leaders

This report helps you benchmark emerging infectious disease therapies and conference activity against leading pharmaceutical and biotechnology companies.

It provides comparative insight into:

  • Clinical development trends

  • Pipeline differentiation

  • Sponsor activity and positioning

  • Late-stage infectious disease therapies

  • Emerging antiviral and antifungal strategies

  • Commercial implications of new clinical data

As a result, you can better understand how leading companies are navigating innovation, competition, and treatment evolution within infectious diseases.

Built on Trusted GlobalData Pharmaceutical and Conference Intelligence

GlobalData’s ESCMID Global 2026 Highlights report is built on proprietary pharmaceutical intelligence, analyst expertise, and direct conference coverage.

Trusted by Fortune 500 pharmaceutical companies, biotechnology firms, investors, and healthcare organizations, GlobalData’s intelligence helps organizations monitor therapeutic innovation and emerging market developments.

In addition, GlobalData’s analysts bring decades of expertise across infectious diseases, pharmaceutical R&D, clinical development, and competitive intelligence.

Act Now to Track Emerging Infectious Disease Therapy Trends

The infectious diseases landscape continues to evolve through pipeline innovation, emerging clinical data, and shifting therapeutic strategies.

This report can help you monitor key conference developments, benchmark competitive activity, and identify strategic opportunities emerging from ESCMID Global 2026.

Enanta Pharmaceuticals
AstraZeneca
Moderna
Shionogi
AICuris
Innovative Molecules
Evotec
Helmholtz-Zentrum fur Umweltforschung
F2G
Scynexis

Table of Contents

1. Introduction

1.1. Table of Contents

1.2. Report Overview

1.3. Abbreviations

2. Conference Overview

2.1. Breakdown of presentations by presentation type

2.2. Top 10 drug mentions by presentation

2.3. Top 10 indications with drug mentions

2.4. Top sponsors by no. of presentations

3. Key Presentations

3.1. Respiratory Syncytial Virus (RSV)

3.1.1. Zelicapivir – Enanta Pharmaceuticals

3.1.2. Nirsevimab – AstraZeneca

3.2. Influenza

3.2.1. mRNA-1010 – Moderna

3.3. COVID-19

3.3.1. Secutrelvir – Shionogi & Co

3.4. Herpes Simplex Virus (HSV)

3.4.1. Pritelivir – AiCuris

3.4.2. Adibelivir (IM-250) – Innovative Molecules

3.5. Chikungunya Virus (CHIKV)

3.5.1. EVT894 – Evotec

3.6. Hepatitis B Virus (HBV)

3.6.1. TherVacB – Helmholtz-Zentrum fur Umweltforschung

3.7. Fungal Infections

3.7.1. Olorofim – F2G

3.7.2. SCY-247 – Scynexis

4. Appendix

4.1. About the Authors

4.2. About GlobalData

4.3. Contact Us

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026: Conference Highlights standard reports
Currency USD
$3,750

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$8,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026: Conference Highlights in real time.

  • Access a live European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026: Conference Highlights dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more